Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral IL-12 Plasmid Electroporation in Cutaneous Lymphoma
NCT01579318Phase 2Terminated
- Sponsor
- OncoSec Medical
- Start
- Jun 2012
- Primary completion
- Jun 2014
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tavokinogene telseplasmid in mycosis fungoides (MF), sponsored by OncoSec Medical. Primary endpoints: Objective Response Rate Assessed by Modified Severity Weighted Assessment Tool (mSWAT) Score in the Skin at 24 weeks and Objective Response Rate Assessed by Modified Severity Weighted Assessment Tool (mSWAT) Composite Global Score at 24 weeks. Started Jun 2012; status: terminated.
02
Drugs
tavokinogene telseplasmid
03
Conditions
mycosis fungoides (MF)
Beyond the preview
Go deeper on NCT01579318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01579318.